Furthermore, the combined treatment with SGLT2 inhibitor and STING agonist 2’3’-cGAMP exerted synergistic antitumor effects in osteosarcoma due to the activation of the STING/IRF3/IFN-β pathway via different mechanisms. The gene discussed is IRF3; the disease is osteosarcoma.